Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Payables (2017 - 2025)

Historic Payables for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $6.4 million.

  • Puma Biotechnology's Payables fell 1495.54% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 1495.54%. This contributed to the annual value of $5.5 million for FY2024, which is 2003.19% down from last year.
  • Latest data reveals that Puma Biotechnology reported Payables of $6.4 million as of Q3 2025, which was down 1495.54% from $5.4 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Payables high stood at $20.0 million for Q3 2021, and its period low was $5.1 million during Q3 2023.
  • For the 5-year period, Puma Biotechnology's Payables averaged around $9.1 million, with its median value being $7.8 million (2023).
  • Its Payables has fluctuated over the past 5 years, first crashed by 6609.5% in 2023, then soared by 7318.79% in 2024.
  • Puma Biotechnology's Payables (Quarter) stood at $11.2 million in 2021, then plummeted by 42.37% to $6.4 million in 2022, then grew by 6.97% to $6.9 million in 2023, then dropped by 20.03% to $5.5 million in 2024, then increased by 15.92% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $5.4 million for Q2 2025, and $6.0 million during Q1 2025.